Partners - Companion Diagnostics & Liquid Biopsy Summit APAC

2024 PARTNERS

2024年のパートナー

2024年合作伙伴

Rakan Kongsi 2024

Expertise Partners

Foundation Medicine

See More:

Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range
of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer
biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. Every day, we are driven to help our partners find answers and take action, enabling more people around the world
to benefit from precision cancer care.
www.foundationmedicine.com

Illumina

See More:

At Illumina, our goal is to apply innovative technologies and revolutionary assays
to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make
the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only
innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions,
rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina’s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

www.illumina.com

Genetron

See More:

Genetron Health is China’s leading precision oncology platform company, specializing in cancer molecular profiling research and applications. Our primary areas of expertise are companion diagnostic partnerships in biopharma solutions and central lab testing services. We offer high quality standard and customized assays based on multi-omics that could accelerate the approval of anti-drug therapies. Our mission is to contribute to eradicating cancer through the use of advanced genomics technologies for cancer detection and treatment.

www.genetronhealth.com

Thermo Fisher Scientific

See More:

Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. We support precision medicine from translational research to the development of companion diagnostics with innovative technologies and service through our Thermo Scientific, Applied Biosystems, Invitrogen, Gibco and Ion Torrent brands.

thermofisher.com

Panel Partner

Almac Diagnostic Services

See More:

Almac Diagnostic Services support global pharma and biotech companies with their biomarker strategies from biomarker discovery through to companion diagnostic partnerships. Almac has clinical and research laboratories in Europe and the USA, alongside strategic partnerships in China, enabling us to support global studies. The services offered fall into three main categories:

Genomic Services
Clinical Trial Assays
Companion Diagnostics

www.almacgroup.com

Guardant

See More:

Guardant Health AMEA is a wholly owned subsidiary of Guardant Health, Inc., a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. Guardant Health has commercially launched Guardant360^®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY™ tests for advanced-stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the commercially launched Shield™ test, aims to address the needs of individuals eligible for cancer screening. For more information, visit guardanthealthamea.com and follow the company on LinkedIn, X and Facebook.

2024 AGENDA

PARTNER

Returning in November 2025 I APAC

View the next meeting in the series here

Returning in November 2025 I APAC

2024 PARTNERS

Expertise Partners

Panel Partner

OUR CONTACT DETAILS

JOIN OUR TEAM

ABOUT US

EXPLORE OUR PRODUCTS

SEARCH